ACXP
Acurx Pharmaceuticals, Inc.NASDAQHealthcare$3.68-5.40%ClosedMarket Cap: $5.8M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.01
P/S
0.00
EV/EBITDA
1284.19
DCF Value
$5,040.79
FCF Yield
81582.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-215.6%
ROA
-103.6%
ROIC
-153.1%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-1.6M | $-1.6M | $-0.67 | — |
| FY 2025 | $0.00 | NaN% | $-8.1M | $-8.0M | $-5.32 | — |
| Q3 2025 | $0.00 | NaN% | $-2.0M | $-2.0M | $-1.23 | — |
| Q2 2025 | $0.00 | NaN% | $-2.3M | $-2.2M | $-1.89 | — |
| Q1 2025 | $0.00 | NaN% | $-2.1M | $-2.1M | $-2.14 | — |
| Q4 2024 | $0.00 | NaN% | $-2.8M | $-2.8M | $-3.27 | — |
| FY 2024 | $0.00 | NaN% | $-14.1M | $-14.1M | $-17.59 | — |
| Q3 2024 | $0.00 | NaN% | $-2.8M | $-2.8M | $-3.45 | — |
| Q2 2024 | $0.00 | NaN% | $-4.1M | $-4.1M | $-5.21 | — |
| Q1 2024 | $0.00 | NaN% | $-4.4M | $-4.4M | $-5.66 | — |
| Q4 2023 | $0.00 | NaN% | $-5.1M | $-5.1M | $-7.60 | — |
| FY 2023 | $0.00 | NaN% | $-14.6M | $-14.6M | $-23.01 | — |